CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
about
Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung diseasePositioning new pharmacotherapies for COPDTherapeutic Potential of Medicinal Plants and Their Constituents on Lung Inflammatory DisordersImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaThe pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers.Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functionsA novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects.Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.Clinical Association of Chemokine (C-X-C motif) Ligand 1 (CXCL1) with Interstitial Pneumonia with Autoimmune Features (IPAF).Chronic Obstructive Pulmonary Disease, Neutrophils and Bacterial Infection: A Complex Web Involving IL-17 and IL-22 UnravelsMyeloid-derived Suppressor Cells are Necessary for Development of Pulmonary Hypertension.Emerging pharmaceutical therapies for COPD.Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease.Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Novel approaches to the management of noneosinophilic asthma.Mycobacteria Manipulate G-Protein-Coupled Receptors to Increase Mucosal Rac1 Expression in the Lungs.Neutrophils in cancer: neutral no more.Addressing corticosteroid insensitivity in adults with asthma.Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications.Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.Commentary: Understanding the Impact of Infection, Inflammation and Their Persistence in the Pathogenesis of Bronchopulmonary Dysplasia.The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primatesNRAS destines tumor cells to the lungs.Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.Two Lovely Black Eyes; Oh, what a surprise!Neutrophils, a candidate biomarker and target for radiation therapy?The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.New Therapies for Asthma and Chronic Obstructive Pulmonary Disease.Roles of Myeloid and Lymphoid Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
P2860
Q26786229-502E5C32-2F3C-45FC-89CA-0455900E3D29Q26798659-BCF04E76-E2E5-4B14-A6A4-6477BA2E31F0Q28067576-AADBCB1A-B821-448A-93DD-98589D8292FFQ28069864-1C53020E-7821-44A3-8111-A3E37EF601E1Q34079756-79173FD6-B470-4943-A76B-DF1D64371FC9Q36041334-B08CF20E-B328-4B51-BB7D-8A37BC3EEE51Q36410084-353A0051-2E4F-467F-BA21-BD58DBFC13EEQ37063651-6C931855-E396-480F-9817-6ED80C880E5CQ37402041-763123B2-B90D-4624-80FC-C1A6A78788C2Q37498876-F4C81771-A9D0-4B8D-A03D-A1B0212EC4E4Q38255466-18171EA7-F24C-4E43-82DF-E1D84F0E35A3Q38597953-EC1AAFCD-67B6-4AB6-A643-EACF3A8B668DQ38645203-1CE15A49-87A9-4126-A294-FC4844C6F0B4Q38673045-286CF9C2-F55D-4B3A-863C-80CEFDDA6B7CQ38675216-48F07350-4F1B-4735-BA18-073B2C79F03AQ38751226-5DE0A09D-2503-4F88-97B0-6BFB2273A1E7Q38756064-F1E30F9B-19BE-4C03-B7C5-DF1D9FF932D6Q38778343-7C1A3212-FDFF-425D-B6AC-D6278185C693Q38860382-4ED21CE0-2AFB-4B9E-9698-246E15999902Q38930984-E4A8BA71-F977-4740-B8F3-4F2B67122296Q38950036-F3ACE683-0237-430D-822F-120F5F450956Q39321350-8AF70A66-64CD-45B9-98F2-FA7D156616F0Q40290635-F718C991-52E1-4B65-A928-A0CC12E1094DQ42325004-C7611FC9-40A3-4A07-85D7-1EA37A01D472Q47161788-900AF021-238C-4D7D-947B-7A51F5F2EE03Q47699381-1A1C854B-5EF5-43A9-BCAD-4317F0BB1E0FQ48583884-C2B51127-FBB8-4E39-8BC2-F4C3CC512B5DQ51631534-F1CF42A1-F910-49EC-A0B0-FED933F1F6AEQ51802063-2054B99F-DDEC-4EF1-BC93-B531DDD42E92Q52599800-01CFADB1-E64D-4EB6-AA44-F132F834CD18Q53645314-B7AAE94D-08D1-4D9A-8F38-32D4A8A4EA36Q55440438-94FA31E5-4B01-47B9-ACD1-95BC8C4B9D45
P2860
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CXCR2 Antagonist MK-7123. A Ph ...... Obstructive Pulmonary Disease.
@en
type
label
CXCR2 Antagonist MK-7123. A Ph ...... Obstructive Pulmonary Disease.
@en
prefLabel
CXCR2 Antagonist MK-7123. A Ph ...... Obstructive Pulmonary Disease.
@en
P2093
P2860
P1476
CXCR2 Antagonist MK-7123. A Ph ...... Obstructive Pulmonary Disease.
@en
P2093
David C Dale
E Rand Sutherland
Elizabeth Rosenberg
Frank Kanniess
Helgo Magnussen
Henrik Watz
Heribert Staudinger
James F Donohue
Paul Stryszak
Stephen I Rennard
P2860
P304
P356
10.1164/RCCM.201405-0992OC
P407
P577
2015-05-01T00:00:00Z